Slideshows Images Quizzes

Primaxin IM

Last reviewed on RxList: 8/19/2008
Primaxin IM Side Effects Center

Last reviewed on RxList 1/31/2016

Primaxin IM (imipenem and cilastatin for injectable suspension) is a combination of an antibiotic, and a drug helps the antibiotic work more effectively by preventing the breakdown of the antibiotic in the kidneys, used to treat severe infections of the lower respiratory tract, skin, stomach, female reproductive organs, and other body systems. Primaxin IM may be available in generic form. Common side effects of Primaxin IM include injection site reactions (swelling, redness, pain, or soreness). Other side effects of Primaxin IM include upset stomach, stomach pain, nausea, vomiting, heartburn, diarrhea, sore throat, vaginal itching or discharge, skin rash or itching, dizziness, tired feeling, numbness or tingling, or ringing in your ears.

The dosage of Primaxin IM for any patient should be based on the location of and severity of the infection, the susceptibility of the infecting pathogen(s), and renal function. The duration of therapy depends upon the type and severity of the infection. Primaxin IM may interact with valproic acid, ganciclovir, probenecid, penicillin antibiotics, or cephalosporin antibiotics. Tell your doctor all medications you are taking. During pregnancy, Primaxin IM should be used only when prescribed. This medication passes into breast milk. Though there have been no reports of harm to nursing infants, consult your doctor before breastfeeding.

Our Primaxin IM (imipenem and cilastatin for injectable suspension) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Primaxin IM Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • fast or pounding heartbeats;
  • diarrhea that is watery or bloody;
  • confusion, tremors, hallucinations, seizure (convulsions);
  • feeling light-headed, fainting;
  • fever, chills, body aches, flu symptoms;
  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash.

Less serious side effects may include:

  • pain, swelling, or redness where the medicine was injected;
  • mild nausea, vomiting, heartburn, or stomach pain;
  • sore throat;
  • vaginal itching or discharge;
  • mild skin rash or itching;
  • dizziness or tired feeling;
  • numbness or tingling; or
  • ringing in your ears.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Primaxin IM (Imipenem and Cilastatin)

Primaxin IM Professional Information

SIDE EFFECTS

PRIMAXIN I.M.

In 686 patients in multiple dose clinical trials of PRIMAXIN I.M., the following adverse reactions were reported:

Local Adverse Reactions

The most frequent adverse local clinical reaction that was reported as possibly, probably, or definitely related to therapy with PRIMAXIN I.M. was pain at the injection site (1.2%).

Systemic Adverse Reactions

The most frequently reported systemic adverse clinical reactions that were reported as possibly, probably, or definitely related to PRIMAXIN I.M. were nausea (0.6%), diarrhea (0.6%), vomiting (0.3%) and rash (0.4%).

Adverse Laboratory Changes

Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:

Hemic: decreased hemoglobin and hematocrit, eosinophilia, increased and decreased WBC, increased and decreased platelets, decreased erythrocytes, and increased prothrombin time.

Hepatic: increased AST, ALT, alkaline phosphatase, and bilirubin.

Renal: increased BUN and creatinine.

Urinalysis: presence of red blood cells, white blood cells, casts, and bacteria in the urine.

Potential ADVERSE EFFECTS:

In addition, a variety of adverse effects, not observed in clinical trials with PRIMAXIN I.M., have been reported with intravenous administration of PRIMAXIN I.V. (Imipenem and Cilastatin for Injection). Those listed below are to serve as alerting information to physicians.

Systemic Adverse Reactions

The most frequently reported systemic adverse clinical reactions that were reported as possibly, probably, or definitely related to PRIMAXIN I.V. (Imipenem and Cilastatin for Injection) were fever, hypotension, seizures (see PRECAUTIONS), dizziness, pruritus, urticaria, and somnolence.

Additional adverse systemic clinical reactions reported possibly, probably, or definitely drug related or reported since the drug was marketed are listed within each body system in order of decreasing severity: Gastrointestinal: pseudomembranous colitis (the onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment, see WARNINGS), hemorrhagic colitis, hepatitis (including fulminant hepatitis), hepatic failure, jaundice, gastroenteritis, abdominal pain, glossitis, tongue papillar hypertrophy, staining of the teeth and/or tongue, heartburn, pharyngeal pain, increased salivation; Hematologic: pancytopenia, bone marrow depression, thrombocytopenia, neutropenia, leukopenia, hemolytic anemia; CNS: encephalopathy, tremor, confusion, myoclonus, seizures, paresthesia, vertigo, headache, psychic disturbances including hallucinations; Special Senses: hearing loss, tinnitus, taste perversion; Respiratory: chest discomfort, dyspnea, hyperventilation, thoracic spine pain; Cardiovascular: palpitations, tachycardia; Renal: acute renal failure, oliguria/anuria, polyuria, urine discoloration; Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, angioneurotic edema, flushing, cyanosis, hyperhidrosis, skin texture changes, candidiasis, pruritus vulvae; Body as a whole: polyarthralgia, asthenia/weakness, drug fever.

Adverse Laboratory Changes

Adverse laboratory changes without regard to drug relationship that were reported during clinical trials or reported since the drug was marketed were:

Hepatic: increased LDH; Hemic: positive Coombs test, decreased neutrophils, agranulocytosis, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils; Electrolytes: decreased serum sodium, increased potassium, increased chloride; Urinalysis: presence of urine protein, urine bilirubin, and urine urobilinogen.

Lidocaine HCl - Refer to the package circular for lidocaine HCl.

Read the entire FDA prescribing information for Primaxin IM (Imipenem and Cilastatin)

Related Resources for Primaxin IM

Related Drugs

Read the Primaxin IM User Reviews »

© Primaxin IM Patient Information is supplied by Cerner Multum, Inc. and Primaxin IM Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors